Concepedia

Martha E. Anderson

ME

Statistics

Publications

26

Citations

3.1K

H-Index

20

Active since

1973

Affiliations

Seagen (United States)(Current)

Fred Hutch Cancer Center

Martha E. Anderson is an author at Seagen (United States) specializing in antibody-drug conjugates, antibody conjugates, and pharmacology.

ORCID

Publications per year

1973–2023

26

Publications

26

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 523 citations

, , +14

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Robert P. Lyon, Jocelyn R. Setter, Tim D. Bovee et al. · Nature Biotechnology · 2014 · 445 citations

, , +16

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

Leia M. Smith, Albina Nesterova, Maureen C. Ryan et al. · British Journal of Cancer · 2008 · 289 citations · Full text

, , +16

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 246 citations

, , +17

Development of orally active inhibitors of protein and cellular fucosylation

Nicole M. Okeley, Stephen C. Alley, Martha E. Anderson et al. · Proceedings of the National Academy of Sciences · 2013 · 192 citations · Full text

, , +17

1–5 of 26